163 related articles for article (PubMed ID: 15202842)
1. Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Sebök B; Tóth M; Anga B; Harangi F; Schneider I
Acta Derm Venereol; 2004; 84(3):229-30. PubMed ID: 15202842
[No Abstract] [Full Text] [Related]
2. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
3. Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.
Nash DT
Am J Cardiol; 1996 Sep; 78(6A):26-31. PubMed ID: 8875972
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin and cancer.
Mascitelli L; Pezzetta F
Int J Clin Pract; 2007 Jan; 61(1):168; author reply 168-9. PubMed ID: 17229191
[No Abstract] [Full Text] [Related]
5. Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Cromwell WC; Ziajka PE
Am J Cardiol; 2000 Nov; 86(10):1123-7. PubMed ID: 11074211
[TBL] [Abstract][Full Text] [Related]
6. [High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit; 2003; 32(6):516-7. PubMed ID: 14639833
[No Abstract] [Full Text] [Related]
7. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
de Graaf L; Brouwers AH; Diemont WL
Br J Clin Pharmacol; 2004 Sep; 58(3):326-8. PubMed ID: 15327593
[TBL] [Abstract][Full Text] [Related]
8. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Sinzinger H; Schmid P; O'Grady J
Atherosclerosis; 1999 Apr; 143(2):459-60. PubMed ID: 10217378
[No Abstract] [Full Text] [Related]
9. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin, rhabdomyolysis, and myotoxicity.
Murinson BB; Maragakis NJ; Jacobson TA
Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
[No Abstract] [Full Text] [Related]
11. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
13. Clinical implications of the biopharmaceutical properties of fluvastatin.
Deslypere JP
Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
[TBL] [Abstract][Full Text] [Related]
14. [Statin-induced rhabdomyolysis and renal failure: also with fluvastatine].
Lado Lado FL; Rodríguez Moreno C; Cinza Sajurjo S; Durán Parrondo C; Pazo Núñez M; Lois Pernas A; Masa Vázquez L
An Med Interna; 2004 May; 21(5):235-7. PubMed ID: 15176926
[TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
16. Acute pancreatitis induced by fluvastatin therapy.
Tysk C; Al-Eryani AY; Shawabkeh AA
J Clin Gastroenterol; 2002; 35(5):406-8. PubMed ID: 12394230
[TBL] [Abstract][Full Text] [Related]
17. A review of the lipid-related effects of fluvastatin.
Liberopoulos EN; Daskalopoulou SS; Mikhailidis DP; Wierzbicki AS; Elisaf MS
Curr Med Res Opin; 2005 Feb; 21(2):231-44. PubMed ID: 15801994
[TBL] [Abstract][Full Text] [Related]
18. Fluvastatin: efficacy and safety in reducing cardiac events.
Chan MY; Lee CH
Expert Opin Pharmacother; 2005 Sep; 6(11):1883-95. PubMed ID: 16144508
[TBL] [Abstract][Full Text] [Related]
19. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
20. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
